Shots:
- The US FDA has approved Ticovac for active immunization to prevent TBE in patients aged ≥1 yrs. The US CDC’s will discuss recommendations regarding the safe and appropriate use of the vaccine
- In clinical trials, safety & immunogenicity of Ticovac were evaluated across two age groups (aged 1-15 yrs. and >16 yrs.). The studies showed seropositivity rates (99.5% & 98.7-100%) following 3 doses respectively while the vaccine was generally well-tolerated with no unexpected AEs or vaccine-related serious AEs observed
- Additionally, real-world studies demonstrated that the vaccine is 96-98.7% effective in people who have received at least 3 doses of the vaccine
Click here to read full press release/ article | Ref: Pfizer | Image: The Wall Street Journal
The post Pfizer’s Ticovac Receives the US FDA’s Approval for the Prevention of Tick-Borne Encephalitis first appeared on PharmaShots.
